0001209191-24-005486.txt : 20240502
0001209191-24-005486.hdr.sgml : 20240502
20240502212745
ACCESSION NUMBER: 0001209191-24-005486
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240501
FILED AS OF DATE: 20240502
DATE AS OF CHANGE: 20240502
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Mancini Marianna
CENTRAL INDEX KEY: 0001838112
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-37355
FILM NUMBER: 24910538
MAIL ADDRESS:
STREET 1: C/O VIKING THERAPEUTICS, INC.
STREET 2: 12340 EL CAMINO REAL, STE 250
CITY: SAN DIEGO
STATE: CA
ZIP: 92130
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Viking Therapeutics, Inc.
CENTRAL INDEX KEY: 0001607678
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 461073877
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 9920 PACIFIC HEIGHTS BLVD, SUITE 350
CITY: SAN DIEGO
STATE: CA
ZIP: 92121
BUSINESS PHONE: 858-704-4660
MAIL ADDRESS:
STREET 1: 9920 PACIFIC HEIGHTS BLVD, SUITE 350
CITY: SAN DIEGO
STATE: CA
ZIP: 92121
4
1
doc4.xml
FORM 4 SUBMISSION
X0508
4
2024-05-01
0
0001607678
Viking Therapeutics, Inc.
VKTX
0001838112
Mancini Marianna
C/O VIKING THERAPEUTICS, INC.
9920 PACIFIC HEIGHTS BLVD, SUITE 350
SAN DIEGO
CA
92121
0
1
0
0
Chief Operating Officer
1
Common Stock, par value $0.00001 per share
2024-05-01
4
M
0
17999
4.68
A
366507
D
Common Stock, par value $0.00001 per share
2024-05-01
4
M
0
87000
4.88
A
453507
D
Common Stock, par value $0.00001 per share
2024-05-01
4
M
0
90000
5.80
A
543507
D
Common Stock, par value $0.00001 per share
2024-05-01
4
M
0
35426
7.77
A
578933
D
Common Stock, par value $0.00001 per share
2024-05-01
4
M
0
51000
8.52
A
629933
D
Common Stock, par value $0.00001 per share
2024-05-01
4
S
0
23746
76.4045
D
606187
D
Common Stock, par value $0.00001 per share
2024-05-01
4
S
0
26142
77.4933
D
580045
D
Common Stock, par value $0.00001 per share
2024-05-01
4
S
0
105343
78.6476
D
474702
D
Common Stock, par value $0.00001 per share
2024-05-01
4
S
0
119946
79.2945
D
354756
D
Common Stock, par value $0.00001 per share
2024-05-01
4
S
0
6248
80.0753
D
348508
D
Stock Option (Right to Buy)
4.68
2024-05-01
4
M
0
17999
0.00
D
2021-03-31
2030-03-31
Common Stock
17999
1
D
Stock Option (Right to Buy)
4.88
2024-05-01
4
M
0
87000
0.00
D
2023-01-03
2032-01-03
Common Stock
87000
87000
D
Stock Option (Right to Buy)
5.80
2024-05-01
4
M
0
90000
0.00
D
2022-01-04
2031-01-04
Common Stock
90000
0
D
Stock Option (Right to Buy)
7.77
2024-05-01
4
M
0
35426
0.00
D
2021-01-03
2030-01-03
Common Stock
35426
18574
D
Stock Option (Right to Buy)
8.52
2024-05-01
4
M
0
51000
0.00
D
2024-01-03
2033-01-03
Common Stock
51000
153000
D
The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 1, 2024.
The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $76.09 to $76.97, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote.
The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $77.00 to $77.99, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote.
The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $78.00 to $78.9983, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote.
The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $79.00 to $79.98, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote.
The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $80.02 to $80.19, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote.
25% of the shares subject to the option vested or will vest on each one year anniversary of the grant date.
One-third of the shares subject to the option vested on each one year anniversary of the grant date.
/s/ Michael Morneau as Attorney-in-Fact
2024-05-02